Orion

R&D

This week in clinical trials: 29th January to 2nd February

Continuing our weekly clinical trial round-ups, here we look at developments in life sciences research and development announced during the week of 29th January to 2nd

R&D

This week in clinical trials: 2nd-5th January 2024

Despite the multiple challenges that faced clinical trials in 2023, according to GlobalData’s Pharmaceutical Intelligence Centre, some 22,338

News

Bayer bags swift OK for Nubeqa in metastatic prostate cancer

Bayer has won a key FDA approval to extend the use of its prostate cancer therapy Nubeqa, as it tries to claim market share from rival drugs and fulfil its aim of building the drug into a €

News

Merck buys into Orion prostate cancer therapy in $290m deal

Merck & Co has added another clinical-stage drug to its oncology pipeline via a licensing agreement with Finland's Orion for ODM-208, a prostate cancer candidate currently in phase 2 te

News

Chasing rivals, Bayer files Nubeqa for new prostate cancer u...

Bayer has filed for approval to extend the use of its prostate cancer therapy Nubeqa as it tries to achieve labelling parity with rival drugs from Pfizer/Astellas and Johnson & Jonson,

Views & Analysis